September 8, 2025 — Leads & Copy — BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) announced an update on its collaboration with Eleison Pharmaceuticals Inc., highlighting the development of a new data ingestion module, bfPREP™, and a planned joint oncology conference submission. The collaboration also involves discussions for a follow-on contract.
BullFrog AI’s bfPREP™ module was initially created to convert over 10,000 pages of clinical trial PDFs into an OMOP-standardized dataset for Eleison. CEO Vin Singh noted that the module transforms legacy clinical trial data into a strategic asset.
Following data ingestion, BullFrog AI used feature engineering and AI-enhanced curation to extend the dataset, categorizing diseases, medications, and lesion descriptors. The structured dataset was then deployed into bfLEAP®, BullFrog AI’s core analytics engine, to identify data-driven patient subgroups.
Matt Cromie, VP Clinical Development at Eleison, expressed satisfaction with the collaboration. BullFrog AI and Eleison are preparing a joint scientific submission to an upcoming oncology conference and exploring further collaboration through a second contract.
BullFrog AI leverages AI and machine learning to advance drug discovery and development. Eleison Pharmaceuticals focuses on developing therapeutics for life-threatening cancers and has partnerships in China, South Korea, and Israel.
Contact: Dave Gentry, RedChip Companies, Inc., 1-407-644-4256, BFRG@redchip.com
Source: BullFrog AI
